AEZS

Aeterna Zentaris Inc. [AEZS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AEZS Stock Summary

Top AEZS Correlated Resources

AEZS


Top 10 Correlated ETFs

AEZS


Top 10 Correlated Stocks

AEZS


In the News

11:19 22 Mar 2023 AEZS

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday , January 19 th at 3 :00 PM ET

08:00 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET

08:36 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.

12:46 22 Mar 2023 AEZS

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.

08:00 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28, 2021, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

01:09 22 Mar 2023 AEZS

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

AEZS Financial details

Company Rating
Neutral
Market Cap
13.18M
Income
-10.94M
Revenue
7.45M
Book val./share
10.18
Cash/share
11.08
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
27 Mar 2023
P/E
-1.4
Forward P/E
-
PEG
0.47
P/S
1.89
P/B
0.26
P/C
0.24
P/FCF
-1.62
Quick Ratio
9.37
Current Ratio
9.82
Debt / Equity
0.35
LT Debt / Equity
0
-
-
EPS (TTM)
-2.11
EPS next Y
-
EPS next Q
-0.47
EPS this Y
-41.67%
EPS next Y
-
EPS next 5Y
-38978.5%
EPS last 5Y
-42.57%
Revenue last 5Y
41.63%
Revenue Q/Q
22.61%
EPS Q/Q
40%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-25%
Inst Own
0.72%
Inst Trans
-14.04%
ROA
-14%
ROE
-18%
ROC
-0.16%
Gross Margin
98%
Oper. Margin
-145%
Profit Margin
-135%
Payout
-
Shs Outstand
4.86M
Shs Float
4.85M
-
-
-
-
Target Price
-
52W Range
2.54-9.75
52W High
-70.44%
52W Low
+33%
RSI
32
Rel Volume
3
Avg Volume
14.91K
Volume
44.73K
Perf Week
1.92%
Perf Month
-29.07%
Perf Quarter
-32.14%
Perf Half Y
-41.54%
-
-
-
-
Beta
1.72548
-
-
Volatility
0.04%, 0.36%
Prev Close
0%
Price
2.66
Change
2.31%

AEZS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
1.5440.880.762.221.14
Net income per share
-28.076.37-8.63-3.11-1.82
Operating cash flow per share
-38.2910.38-15.33-2.51-1.87
Free cash flow per share
-38.310.36-15.33-2.51-2.01
Cash per share
1322.0711.214.7714.2
Book value per share
-4.652.9-3.528.0411.53
Tangible book value per share
-19.2-9.68-15.082.649.62
Share holders equity per share
-4.652.9-3.528.0411.53
Interest debt per share
0.130.422.14-0.340.04
Market cap
35.3M48.34M15.92M17.48M40.83M
Enterprise value
27.52M33.82M8.98M-6.61M-24.31M
P/E ratio
-2.111.54-2.63-3.42-4.88
Price to sales ratio
38.251.829.924.797.76
POCF ratio
-1.547.08-1.48-4.23-4.76
PFCF ratio
-1.547.09-1.48-4.23-4.43
P/B Ratio
-12.6925.35-6.461.320.77
PTB ratio
-12.6925.35-6.461.320.77
EV to sales
29.821.2616.89-1.81-4.62
Enterprise value over EBITDA
-1.373.39-1.691.262.92
EV to operating cash flow
-1.24.96-0.841.62.83
EV to free cash flow
-1.24.96-0.841.62.64
Earnings yield
-0.480.09-0.38-0.29-0.2
Free cash flow yield
-0.650.14-0.67-0.24-0.23
Debt to equity
-8.9812.12-9.111.820.51
Debt to assets
1.130.921.120.650.34
Net debt to EBITDA
0.39-1.451.34.617.84
Current ratio
1.632.91.935.569.12
Interest coverage
-307.6535.4-17.277.75-412.9
Income quality
1.361.631.780.811.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
8.880.3312.431.31.12
Research and developement to revenue
11.60.113.450.411.25
Intangibles to total assets
0.390.330.40.240.11
Capex to operating cash flow
00000.07
Capex to revenue
0000-0.12
Capex to depreciation
-0.04-0.1600-4.41
Stock based compensation to revenue
0.20.021.490.020.06
Graham number
54.220.3826.1523.7321.73
ROIC
-3.53-0.81-3.090.50.17
Return on tangible assets
-1.240.25-0.51-0.18-0.12
Graham Net
-27.93-12.55-19.310.98.91
Working capital
3.61M10.66M5.25M22.87M63.05M
Tangible asset value
-11.49M-6.37M-10.55M4.34M44.23M
Net current asset value
-15.6M-6.85M-11.53M3.82M43.7M
Invested capital
00-0.370.010
Average receivables
293K257.5K476K1.17M2.68M
Average payables
1.63M1.25M1.18M1.14M1.06M
Average inventory
321.5K441.5K721.5K612K47K
Days sales outstanding
87.393.99451.45168.01255.01
Days payables outstanding
0222.4967.7186.993.79K
Days of inventory on hand
041.631.07K3.31296.06
Receivables turnover
4.1891.430.812.171.43
Payables turnover
01.640.381.950.1
Inventory turnover
08.770.34110.331.23
ROE
6.042.22.45-0.39-0.16
Capex per share
-0.01-0.0100-0.14

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-09-30
Revenue per share
0.120.120.720.310.38
Net income per share
-0.42-0.35-0.66-0.54-0.7
Operating cash flow per share
-0.75-0.31-0.5-0.3-0.81
Free cash flow per share
-0.75-0.31-0.52-0.3-0.81
Cash per share
14.4114.0213.4613.111.08
Book value per share
12.6512.3510.9210.9510.18
Tangible book value per share
10.7810.59.129.188.62
Share holders equity per share
12.6512.3510.9210.9510.18
Interest debt per share
0.030.040.030.030.02
Market cap
106.28M90.97M43.1M44.63M18.62M
Enterprise value
36.53M23.17M-22.04M-18.81M-35.11M
P/E ratio
-13.03-13.39-3.38-4.23-1.36
Price to sales ratio
177.43151.1212.4129.4210.01
POCF ratio
-29.24-61.14-17.86-30.54-4.72
PFCF ratio
-29.21-60.93-16.99-30.42-4.71
P/B Ratio
1.731.520.810.840.38
PTB ratio
1.731.520.810.840.38
EV to sales
60.9938.49-6.35-12.4-18.87
Enterprise value over EBITDA
-18.3-13.957.057.2210.37
EV to operating cash flow
-10.05-15.579.1312.878.9
EV to free cash flow
-10.04-15.528.6912.828.88
Earnings yield
-0.02-0.02-0.07-0.06-0.18
Free cash flow yield
-0.03-0.02-0.06-0.03-0.21
Debt to equity
0.370.370.510.440.35
Debt to assets
0.270.270.340.30.26
Net debt to EBITDA
34.9440.8220.8424.3515.86
Current ratio
16.4315.169.1211.849.82
Interest coverage
-302-454.502.81K0
Income quality
1.780.880.760.551.15
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.752.040.511.031.11
Research and developement to revenue
1.231.331.351.581.77
Intangibles to total assets
0.110.110.110.110.11
Capex to operating cash flow
000.0500
Capex to revenue
-0.01-0.01-0.0400
Capex to depreciation
-0.08-0.15-3.1-0.17-0.27
Stock based compensation to revenue
0.430.030.010.020.24
Graham number
10.949.8612.711.5712.7
ROIC
0.040.030.070.050.09
Return on tangible assets
-0.03-0.02-0.04-0.04-0.06
Graham Net
9.99.68.458.697.89
Working capital
70.18M67.62M63.05M61.43M52.64M
Tangible asset value
52.27M50.96M44.23M44.57M41.85M
Net current asset value
51.72M50.28M43.7M43.91M41.42M
Invested capital
00000
Average receivables
1.28M1.2M2.29M2.92M0
Average payables
826.5K639.5K803K978K0
Average inventory
59.5K58K65K175.5K0
Days sales outstanding
224.32136.0595.23128.92100.74
Days payables outstanding
4.55K1.95K4.67K1.16K4.63K
Days of inventory on hand
442.5165.48365316.711.53K
Receivables turnover
0.40.660.950.70.89
Payables turnover
0.020.050.020.080.02
Inventory turnover
0.20.540.250.280.06
ROE
-0.03-0.03-0.06-0.05-0.07
Capex per share
00-0.0300

AEZS Frequently Asked Questions

What is Aeterna Zentaris Inc. stock symbol ?

Aeterna Zentaris Inc. is a US stock , located in Summerville of Sc and trading under the symbol AEZS

What is Aeterna Zentaris Inc. stock quote today ?

Aeterna Zentaris Inc. stock price is $2.66 today.

Is Aeterna Zentaris Inc. stock public?

Yes, Aeterna Zentaris Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap